eFFECTOR Therapeutics Completes $38.6 Million Series C Financing

SAN DIEGO, July 24, 2017 – eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulators for the treatment of cancer, today announced that the company has raised $38.6M in Series C financing. Pfizer Venture Investments (PVI) led the round and was joined by additional new investors including Alexandria Venture Investments. All existing investors […]

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a Novel Immuno-oncology Combination in Microsatellite Stable Colorectal Cancer

SAN DIEGO, June 20, 2017 – eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC).

eFFECTOR Therapeutics Presents Phase 1 Data on eFT508, Its Lead Product Candidate, at ASCO 2017

SAN DIEGO, June 5, 2017 – Today, eFFECTOR Therapeutics presented Phase 1 clinical trial data at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. In a poster entitled, “A Phase 1 Dose Escalation Study of eFT508, an Inhibitor of Mitogen-Activated Protein Kinase-Interacting Serine/Threonine Kinase-1 (MNK-1) and MNK-2 in Patients with Advanced Solid Tumors,” […]

eFFECTOR Therapeutics Presents Positive Preclinical Data on Lead Product Candidate at AACR 2017

SAN DIEGO, April 3, 2017 – eFFECTOR Therapeutics yesterday presented positive preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2017 in Washington, D.C. In a poster entitled “eFT508, a potent and highly selective inhibitor of MNK1/2, regulates immune checkpoint and cytokine expression promoting anti-tumor immunity,” eFFECTOR scientists presented data demonstrating that eFT508, […]

eFFECTOR Therapeutics’ Lead Product Candidate, eFT508, Receives Orphan Designation from FDA for Treatment of Diffuse Large B-Cell Lymphoma

SAN DIEGO, March 9, 2017 – eFFECTOR Therapeutics today announced that its lead product candidate, eFT508, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin lymphoma. eFT508 is a potent, highly selective inhibitor of MNK1 and […]

eFFECTOR Therapeutics Appoints Jeremy Barton, M.D., as Chief Medical Officer

SAN DIEGO, September 15, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that Jeremy Barton, M.D., has joined eFFECTOR as chief medical officer. Dr. Barton brings a long and successful track record in oncology drug development to eFFECTOR, having held leadership positions at large […]

eFFECTOR Therapeutics to Present at the American Association for Cancer Research 2016 Annual Meeting

SAN DIEGO, March 18, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced the preclinical profile of lead product candidate eFT508 will be presented at a special drug development track session titled “New Drugs on the Horizon 2” at the Annual Meeting of the American […]

eFFECTOR Therapeutics Increases its Series B Financing Round to $56M

SAN DIEGO, February 19, 2016 — eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced it has increased its Series B financing to a total of $56M.

eFFECTOR Therapeutics Initiates Dosing in Phase 1/2 Clinical Trial of eFT508 in Solid Tumors

SAN DIEGO, January 6, 2016 – eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced that dosing has begun in a Phase 1/2 dose-escalation and cohort-expansion study of eFT508 in patients with advanced solid tumors. eFT508 is the company’s potent, highly selective oral inhibitor of MNK1 and […]

eFFECTOR Therapeutics Raises $40 Million Series B Financing

SAN DIEGO, December 22, 2015 – eFFECTOR Therapeutics, a biopharmaceutical company developing translation regulators for the treatment of cancer, today announced that it has received $40 million in a Series B financing following the advancement of its lead program toward clinical trials. The financing was led by Altitude Life Science Ventures and joined by AbbVie Biotech Ventures and BioMed Ventures. […]